论文部分内容阅读
零售连锁药店慢病管理之路众所周知,中国的医药零售市场是一个巨火的市场,尤其是在处方外流工作即将深入开展的现在,医药零售市场会迎来更多的机遇。但对于众多的医药门店来说,机遇的同时,却是更为激烈的市场竞争,尤其自2015年7月1日新版GSP(《药品经营质量管理规范》)实施开始,中国近43万家医药门店才真正进入了“深水区”。零售药店的板块中,单体药店有26.3万家,占了60.6%,新版GSP实施后,单体药店相较于连锁药店而言,承担了更多的政策压力,
As we all know, China’s pharmaceutical retail market is a giant fire market, especially in the outflow of prescriptions to be carried out in depth now, the pharmaceutical retail market will usher in more opportunities. However, for many pharmaceutical stores, opportunities are at the same time more intense market competition. In particular, since the implementation of the new version of GSP (“Quality Management Practices for Pharmaceutical Products”) on July 1, 2015, nearly 430,000 pharmaceuticals Stores really entered the “deep water ”. Retail pharmacies in the plate, single pharmacies have 26.3 million, accounting for 60.6%, after the implementation of the new GSP, pharmacies compared to pharmacies chain pharmacy, bear more pressure on the policy,